
Stéphane Bolduc

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/804219/publications.pdf Version: 2024-02-01



STÃ OPHANE BOLDUC

#	Article	IF	CITATIONS
1	Comprehensive overview of the available pharmacotherapy for the treatment of non-neurogenic overactive bladder in children. Expert Opinion on Pharmacotherapy, 2022, , 1-12.	1.8	2
2	Bladder cancer cell lines adapt their aggressiveness profile to oxygen tension. Oncology Letters, 2022, 24, .	1.8	0
3	Endocrine-disrupting effects of bisphenols on urological cancers. Environmental Research, 2021, 195, 110485.	7.5	18
4	Immunocompetent Human 3D Organ-Specific Hormone-Responding Vaginal Mucosa Model of HIV-1 Infection. Tissue Engineering - Part C: Methods, 2021, 27, 152-166.	2.1	6
5	Reconstruction of Vascular and Urologic Tubular Grafts by Tissue Engineering. Processes, 2021, 9, 513.	2.8	8
6	Genitourinary Tissue Engineering: Reconstruction and Research Models. Bioengineering, 2021, 8, 99.	3.5	9
7	Bisphenol A Alters the Energy Metabolism of Stromal Cells and Could Promote Bladder Cancer Progression. Cancers, 2021, 13, 5461.	3.7	10
8	Heat-Inactivation of Fetal and Newborn Sera Did Not Impair the Expansion and Scaffold Engineering Potentials of Fibroblasts. Bioengineering, 2021, 8, 184.	3.5	5
9	Use of a magnetic double J stent in pediatric patients: A case–control study at two Canadian pediatric centers. Journal of Pediatric Surgery, 2020, 55, 486-489.	1.6	10
10	Innovative Human Three-Dimensional Tissue-Engineered Models as an Alternative to Animal Testing. Bioengineering, 2020, 7, 115.	3.5	72
11	Case – Bilateral and recurrent pediatric cystic nephroma associated with DICER1 mutation. Canadian Urological Association Journal, 2020, 15, E290-E292.	0.6	0
12	A prospective, multisite study analyzing the percentage of urological cases that can be completely managed by telemedicine. Canadian Urological Association Journal, 2020, 14, 319-321.	0.6	11
13	Prevascularized Tissue-Engineered Human Vaginal Mucosa: In Vitro Optimization and In Vivo Validation. Tissue Engineering - Part A, 2020, 26, 811-822.	3.1	19
14	Conditioned medium produced by fibroblasts cultured in low oxygen pressure allows the formation of highly structured capillary-like networks in fibrin gels. Scientific Reports, 2020, 10, 9291.	3.3	17
15	A randomized, crossover trial comparing the efficacy and safety of fesoterodine and extended-release oxybutynin in children with overactive bladder with 12-month extension on fesoterodine: The FOXY study. Canadian Urological Association Journal, 2020, 14, 192-198.	0.6	7
16	Human Organ-Specific 3D Cancer Models Produced by the Stromal Self-Assembly Method of Tissue Engineering for the Study of Solid Tumors. BioMed Research International, 2020, 2020, 1-23.	1.9	28
17	How far are they coming from?. Canadian Urological Association Journal, 2019, 13, 391-394.	0.6	2
18	Biological Assessment of Zn–Based Absorbable Metals for Ureteral Stent Applications. Materials, 2019, 12, 3325.	2.9	12

STéPHANE BOLDUC

#	Article	IF	CITATIONS
19	Collagen hollow structure for bladder tissue engineering. Materials Science and Engineering C, 2019, 102, 228-237.	7.3	9
20	Cancer-associated fibroblasts induce epithelial–mesenchymal transition of bladder cancer cells through paracrine IL-6 signalling. BMC Cancer, 2019, 19, 137.	2.6	190
21	Confirmed testicular mass on ultrasound: no evidence on histology Report of two cases in teenagers. Canadian Urological Association Journal, 2019, 14, E101-E103.	0.6	Ο
22	Exosomes Induce Fibroblast Differentiation into Cancer-Associated Fibroblasts through TGFβ Signaling. Molecular Cancer Research, 2018, 16, 1196-1204.	3.4	200
23	Engineering Tissues without the Use of a Synthetic Scaffold: A Twenty-Year History of the Self-Assembly Method. BioMed Research International, 2018, 2018, 1-13.	1.9	22
24	Inexpensive production of near-native engineered stromas. Journal of Tissue Engineering and Regenerative Medicine, 2017, 11, 1377-1389.	2.7	27
25	Urothelial cell expansion and differentiation are improved by exposure to hypoxia. Journal of Tissue Engineering and Regenerative Medicine, 2017, 11, 3090-3099.	2.7	16
26	Long-Term Safety and Efficacy of Solifenacin in Children and Adolescents with Overactive Bladder. Journal of Urology, 2017, 198, 928-936.	0.4	17
27	Dual Therapy for Refractory Overactive Bladder in Children: AÂProspective Open-Label Study. Journal of Urology, 2017, 197, 1158-1163.	0.4	39
28	Tissue-engineered human 3D model of bladder cancer for invasion study and drug discovery. Biomaterials, 2017, 145, 233-241.	11.4	47
29	Novel three-dimensional autologous tissue-engineered vaginal tissues using the self-assembly technique. Translational Research, 2017, 180, 22-36.	5.0	19
30	Adherence to antimuscarinics in children with overactive bladder. Paediatrics and Child Health, 2017, 22, 255-258.	0.6	8
31	Vesicoureteral reflux: From prophylaxis to surgery. Canadian Urological Association Journal, 2017, 11, 13.	0.6	19
32	Dimercaptosuccinic acid scintigraphy vs. ultrasound for renal parenchymal defects in children. Canadian Urological Association Journal, 2017, 11, 260-4.	0.6	10
33	Overactive bladder in children. Canadian Urological Association Journal, 2017, 11, 74.	0.6	28
34	Origin of Serum Affects Quality of Engineered Tissues Produced by the Self-Assembly Approach. Scientifica, 2016, 2016, 1-10.	1.7	4
35	Prospective Pilot Study of Mirabegron in Pediatric Patients with Overactive Bladder. European Urology, 2016, 70, 9-13.	1.9	78
36	Clinical challenges in tissue-engineered urethral reconstruction. Translational Andrology and Urology, 2016, 5, 267-270.	1.4	8

STéPHANE BOLDUC

#	Article	IF	CITATIONS
37	Lysophosphatidic acid enhances collagen deposition and matrix thickening in engineered tissue. Journal of Tissue Engineering and Regenerative Medicine, 2015, 9, E65-E75.	2.7	21
38	Optimization of the current self-assembled urinary bladder model: Organ-specific stroma and smooth muscle inclusion. Canadian Urological Association Journal, 2015, 9, 599.	0.6	7
39	Demonstration of the direct impact of ketamine on urothelium using a tissue engineered bladder model. Canadian Urological Association Journal, 2015, 9, 613.	0.6	16
40	Maintenance of bladder urothelia integrity and successful urothelialization of various tissue-engineered mesenchymes in vitro. In Vitro Cellular and Developmental Biology - Animal, 2015, 51, 922-931.	1.5	1
41	Adipose-derived stromal cells for the reconstruction of a human vesical equivalent. Journal of Tissue Engineering and Regenerative Medicine, 2015, 9, E135-E143.	2.7	28
42	Anticancer properties of chitosan on human melanoma are cell line dependent. International Journal of Biological Macromolecules, 2015, 72, 370-379.	7.5	84
43	Efficacy of dextranomer hyaluronic acid and polyacrylamide hydrogel in endoscopic treatment of vesicoureteral reflux: A comparative study. Canadian Urological Association Journal, 2015, 9, 202.	0.6	8
44	Double anticholinergic therapy for refractory neurogenic and non-neurogenic detrusor overactivity in children: Long-term results of a prospective open-label study. Canadian Urological Association Journal, 2014, 8, 175.	0.6	18
45	Intrascrotal extratesticular schwannoma: A first pediatric case. Canadian Urological Association Journal, 2014, 8, 279.	0.6	7
46	Long-term use of solifenacin in pediatric patients with overactive bladder: Extension of a prospective open-label study. Canadian Urological Association Journal, 2014, 8, 118.	0.6	33
47	Prospective Study of Polydimethylsiloxane vs Dextranomer/Hyaluronic Acid Injection for Treatment of Vesicoureteral Reflux. Journal of Urology, 2014, 192, 1794-1800.	0.4	19
48	Strategies to Reconstruct a Functional Urethral Substitute by Self-assembly Method. Procedia Engineering, 2013, 59, 193-200.	1.2	4
49	Early detection of prostate cancer local recurrence by urinary prostate-specific antigen. Canadian Urological Association Journal, 2013, 3, 213.	0.6	5
50	Learning curve for TIP urethroplasty: A single-surgeon experience. Canadian Urological Association Journal, 2013, 7, 789.	0.6	19
51	Tissue Engineering of Urinary Bladder and Urethra: Advances from Bench to Patients. Scientific World Journal, The, 2013, 2013, 1-13.	2.1	87
52	Urinary PSA: a potential useful marker when serum PSA is between 2.5 ng/mL and 10 ng/mL. Canadian Urological Association Journal, 2013, 1, 377.	0.6	55
53	An endothelialized urothelial cell-seeded tubular graft for urethral replacement. Canadian Urological Association Journal, 2013, 7, 4.	0.6	32
54	Factors predicting overall success: a review of 747 microsurgical vasovasostomies. Canadian Urological Association Journal, 2013, 1, 388.	0.6	38

STéPHANE BOLDUC

#	Article	IF	CITATIONS
55	An endothelialized urothelial cell-seeded tubular graft for urethral replacement. Canadian Urological Association Journal, 2013, 7, E4-9.	0.6	14
56	Bladder substitute reconstructed in a physiological pressure environment. Journal of Pediatric Urology, 2011, 7, 276-282.	1.1	30
57	Mechanical Stimuli-induced Urothelial Differentiation in a Human Tissue-engineered Tubular Genitourinary Graft. European Urology, 2011, 60, 1291-1298.	1.9	56
58	Production of an Optimized Tissue-Engineered Pig Connective Tissue for the Reconstruction of the Urinary Tract. Tissue Engineering - Part A, 2011, 17, 1625-1633.	3.1	13
59	<i>In Vitro</i> Reconstruction of an Autologous, Watertight, and Resistant Vesical Equivalent. Tissue Engineering - Part A, 2010, 16, 1539-1548.	3.1	57
60	Prospective Open Label Study of Solifenacin for Overactive Bladder in Children. Journal of Urology, 2010, 184, 1668-1673.	0.4	55
61	Tissue Engineering of a Genitourinary Tubular Tissue Graft Resistant to Suturing and High Internal Pressures. Tissue Engineering - Part A, 2009, 15, 197-202.	3.1	46
62	Double Anticholinergic Therapy for Refractory Overactive Bladder. Journal of Urology, 2009, 182, 2033-2039.	0.4	47
63	In vitro reconstruction of a tissue-engineered endothelialized bladder from a single porcine biopsy. Journal of Pediatric Urology, 2006, 2, 261-270.	1.1	47